BACKGROUND: Lymph node metastasis is a poor prognostic factor for biliary tract cancers (BTCs). The optimal management of patients who have BTC with positive regional lymph nodes, including the impact of surgery and adjuvant therapy (AT), is unclear. METHODS: This was a retrospective cohort study of patients who had T1-T3N1M0 gallbladder cancer (GBC) and intrahepatic cholangiocarcinoma (IHC) in the National Cancer Database (2004Database ( -2012. Patients were classified by treatment approach (nonoperative, surgery, surgery plus AT). Associations between the overall risk of death and treatment strategy were evaluated with multivariable Cox regression. RESULTS: Rates of surgical resection were 84.1% for patients with GBC (n 5 1335) and 36.6% for those with IHC (n 5 1009). The median overall survival of patients in the nonoperative, surgery, and surgery plus AT group was 11.6, 13.3, and 19.6 months, respectively, for those with GBC (log-rank P < .001), and 12.7, 16.2, and 22.6 months, respectively, for those with IHC (log-rank P < .001), respectively. Compared with nonoperative therapy, surgery with or without AT was associated with a lower risk of death from GBC (surgery with AT: hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.48-0.73; surgery without AT: HR, 0.71; 95% CI, 0.56-0.89) and from IHC (surgery with AT: HR, 0.52; 95% CI, 0.42-0.63; surgery without AT: HR, 0.70; 95% CI, 0.56-0.87). AT that included radiation was associated with a lower risk of death relative to surgery alone for patients with GBC regardless of margin status (margin-negative resection: HR, 0.66; 95% CI, 0.52-0.84; margin-positive resection: HR, 0.54; 95% CI, 0.39-0.75), but adjuvant chemotherapy alone was not. For patients with IHC, no survival benefit was detected with adjuvant chemotherapy or radiation for those who underwent either margin-positive or margin-negative resection. CONCLUSIONS: The best outcomes for patients who have lymph node-positive BTCs are associated with margin-negative resection and, in those who have GBC, the inclusion of adjuvant chemotherapy with radiation regardless of margin status. Cancer 2018;124:74-83.
INTRODUCTION
Biliary tract cancers (BTCs) are rare, aggressive malignancies that often present as late-stage disease and have a poor prognosis. Surgical resection provides the only chance for a cure, but recurrence rates are high, and long-term survival rates after curative-intent surgery range from 20% to 35%. Adequate lymph node evaluation has been proposed as an important part of BTC staging because of its prognostic value, 1 ,2 yet the performance of lymphadenectomy in the United States is highly variable. 3, 4 In turn, lymph node involvement has been consistently linked to worse outcomes for patients with BTC, such that the presence of lymph node disease may contribute to a decision for nonoperative management. Indeed, some have questioned the value of surgery for lymph node-positive BTCs in light of series reporting no long-term survivors among patients with lymph node-positive gallbladder cancer (GBC) 5, 6 and survival among those with lymph nodepositive intrahepatic cholangiocarcinoma (IHC) approaching the survival of patients with unresectable disease. 7 For many gastrointestinal cancers, chemotherapy and/or radiation are increasingly used as adjuvant therapy in an effort to improve locoregional control, address early systemic disease, and ultimately prolong survival. However, the extent to which these strategies are beneficial for BTCs remains unclear. Before the recent reporting of results from the BIL-CAP trial (adjuvant capecitabine for biliary tract cancer), which demonstrated a survival benefit from capecitabine over observation after complete BTC resection, 8 there had been no level I data to support any specific adjuvant therapy; and the available literature, mostly derived from small, retrospective, institutional studies, had provided contradictory results. Furthermore, the generalizability of results from the only previous phase 3 trial evaluating adjuvant therapy for BTCs is unclear because of the high rate of margin-positive resection (R1) and because the chemotherapy regimen and schedule evaluated in this study are uncommonly used in contemporary practice. 9 Additional prospective, randomized trials of adjuvant therapy for localized BTCs are either ongoing or have recently finished accrual. 10, 11 Given existing uncertainty regarding the optimal management of BTC and the dearth of data about the benefits of both resection and adjuvant therapy for lymph nodepositive disease, we used a national cancer registry to ascertain treatment patterns for patients with lymph nodepositive BTC. Although we recognize the disparate nature of IHC, GBC, and extrahepatic cholangiocarcinoma (EHC), we believed it was important to attempt to study each, because they are included in all major randomized trials of adjuvant therapy for BTC [8] [9] [10] [11] and because the results generated herein could provide novel and potentially useful information for the treatment of these rare malignancies. The main objectives of this study were to understand the value of surgical resection in patients with lymph nodepositive BTC and to evaluate any survival benefit associated with the receipt of adjuvant therapy.
MATERIALS AND METHODS

Data
This was a retrospective cohort study using the National Cancer Database (NCDB), a prospective, hospital-based cancer registry that collects and reports data on greater than 70% of incident cancers diagnosed at over 1500 Commission on Cancer-accredited centers in the United States. It is a joint project of the American College of Surgeons' Commission on Cancer and the American Cancer Society. This study was approved by the Institutional Review Board of the Baylor College of Medicine and the Michael E. DeBakey Veterans Affairs Medical Center Research and Development Committee.
Study Participants
Between 2004 and 2012, patients between ages 18 and 79 years who had a diagnosis of BTC (GBC, n 5 20,142; IHC, n 5 22,441; and EHC, n 5 1342) were identified. Sequential exclusions are displayed in Figure 1A (GBC) and Figure 1B (IHC) and were applied to identify patients who had T1-T3N1M0 disease. Similar exclusions were applied to patients with EHC; however, because of the small number of patients who ultimately fit the inclusion criteria (n 5 54, including only 15 who underwent surgery), EHC was dropped from the study altogether. For patients who underwent surgery, positive lymph node status was defined based only on pathologic staging data. For patients who received treatment without surgery, this definition was preferentially based on pathologic data when available (ie, biopsy-proven lymph node involvement) or on clinical staging for those without pathologic data. All included patients had histologic confirmation of their disease, received treatment at the reporting hospital, and lived >30 days after diagnosis. The exclusion based on treatment at the reporting facility was to enhance the accuracy of treatment ascertainment.
Variables
Treatment strategies were categorized as no treatment, nonoperative therapy (ie, chemotherapy and/or radiation), surgery only, and surgery plus adjuvant therapy. Adjuvant therapy was further categorized based on the adjuvant modality or modalities received. When both chemotherapy and radiation are received, the NCDB does not provide data to allow ascertainment of whether they were provided concurrently, sequentially, or both concurrently and sequentially. Therefore, patients who received adjuvant treatments were primarily categorized based on the receipt of radiation (received adjuvant chemotherapy and radiotherapy [ACR] , received only adjuvant chemotherapy [AC], or received only adjuvant radiotherapy [AR]).
Analysis
Standard descriptive statistics were used to evaluate categorical and continuous variable distributions. The primary outcome of interest was overall survival (OS), which was defined as the time from diagnosis to the date of either death or last contact. Analyses were conducted in a disease-specific fashion. In all analyses that focused only on surgical patients, those who received with preoperative therapy or single-modality AR were omitted because of the small number of patients who were managed with these approaches (GBC, n 5 34; IHC, n 5 3), as were patients for whom treatment sequencing was unknown. The Kaplan-Meier method and log-rank tests were used to compare OS across treatment groups. The association between treatment approach and the risk of death was evaluated using multivariable Cox regression. Model covariates were selected in a nonparsimonious fashion and included age, sex, race, insurance type, income, education, comorbidity, treatment facility type, tumor grade, and tumor classification stage. The assumption of proportional hazards was graphically evaluated. Sensitivity analyses were also conducted and were stratified by pathologic margin status (positive or negative). To address underlying survivor treatment bias, a 90-day landmark (whereby patients who did not survive past 90 days after surgery were excluded) was applied for all time-to-event analyses. 12 In our cohort, 16.3% of patients had at least 1 missing covariate data point; however, OS at 5 years was not significantly different among patients with and without missing data (11.7% vs 17.3%, respectively; log-rank P 5 .257). To deal with missing values, modeling was conducted in both a case-complete fashion and using multiple imputation by chained equations. Similar results were obtained; thus, and imputed results are presented. Statistical comparisons were 2-sided and were considered significant at P values < .05. All analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC).
RESULTS
Patient Demographic and Clinical Characteristics
Demographic, clinical, tumor, and treatment characteristics of the included patients with BTC are detailed in Table 1 . Our final analytic cohorts included 1335 patients with lymph node-positive GBC and 1009 patients with lymph node-positive IHC. Compared with IHC, GBC disproportionately affected women (72% vs 50% for were more likely to have been readmitted within 30 days of discharge (12.2% vs 6%; P 5 .04).
Survival Analysis
Survival benefit associated with surgery
Among the patients with GBC, the median OS was 11.6 months for those who received nonsurgical therapy, 13.3 months for those who underwent surgery alone, and 19.6 months for those who underwent surgery and received adjuvant therapy. By comparison, the median OS for patients who received no treatment was 8.3 months (logrank P < .001) ( Fig. 2A) . Among the patients with IHC, the respective rates were 12.7, 16.2, 22.6, and 9.6 months (log rank P < .001) (Fig. 2B ).
Relative to those who received nonsurgical therapy, patients who underwent surgery alone had a lower risk of death (Table 3 
Survival benefit associated with adjuvant therapy
Among patients with GBC who underwent surgical treatment, the median OS was 13.3 months with surgery alone, 14.3 months with surgery plus AC, and 24.7 months with surgery plus ACR. Among those with IHC, these rates were 16.2, 22.2, and 24.1 months, respectively.
Among the surgical patients (Table 3 , Surgery patients only), the addition of ACR was associated with a survival advantage for those who had GBC, regardless of margin status (margin-negative resection: HR, 0.66; 95% CI, 0.51-0.85; margin-positive resection: HR, 0.44; 95% CI, 0.30-0.64). Single-modality AC, conversely, was not. For IHC, there was no survival advantage observed with the addition of either AC or ACR, whether surgical margins were positive or not.
DISCUSSION
BTCs present a management challenge because of the lack of high-quality data to guide clinical decisions at the point of care. Lymph node involvement is a negative prognostic factor for all BTCs, but the optimal treatment approach for lymph node-positive BTC remains unclear. In this regard, the data from the current cohort of patients with lymph node-positive GBCs and IHCs support timely and important conclusions. Surgical resection, even in this setting of lymph node-positive disease, is associated with a significant improvement in survival compared with nonsurgical treatment, which, conversely, confers little benefit relative to no treatment. Demonstration of the benefit of surgery is especially important for patients with lymph node-positive IHC in light of the low rate of surgical resection (37%) for this cohort, which may reflect uncertainty or reluctance on the part of providers to operate on these patients, who are currently considered by national staging guidelines to have stage IV disease. 1 Moreover, the receipt of ACR is associated with a survival benefit for all patients who have lymph node-positive GBC, whereas AC alone does not appear to be beneficial. Our data do not demonstrate a clear survival benefit from either adjuvant strategy for patients with IHC.
The high rates of locoregional and distant recurrence in patients with resected, lymph node-positive BTC provide a natural incentive for clinicians to consider adjuvant chemotherapy and/or radiation. Yet this practice has been based more on expert opinion than on actual data. For both GBC and IHC, most contemporary management guidelines regarding the receipt of adjuvant therapy are derived from retrospective series, many of which provide inconclusive or even conflicting results. [13] [14] [15] [16] In a metaanalysis that included patients with all types of BTCs, Horgan and colleagues concluded that adjuvant therapy 17 In disease-specific analyses, the benefit of adjuvant therapy for patients with lymph node-positive GBC, calculated from 2 studies, was nonsignificant (HR, 0.58; 95% CI, 0.29-1.18); whereas the data from patients with IHC were based on only 1 study with a total of 11 patients. In a separate metaanalysis focusing on IHC, Mavros et al reported that AC or AR did not improve survival, although only two-thirds of their patients underwent lymphadenectomy and, among those, only 1 of 3 had lymph node-positive disease. 18 Therefore, to our knowledge, our data are derived from the largest cohort of lymph node-positive patients with GBC and IHC in the published literature to date and provide important information about the utility of adjuvant therapy in the multimodal management of each disease.
Until results from the BILCAP trial were recently published, the only randomized trial providing data on the effect of adjuvant therapy on long-term survival in patients with BTC was a Japanese multi-institutional study that compared an adjuvant regimen of mitomycin C and 5-fluorouracil versus observation after surgical resection in patients with pancreaticobiliary cancers. 9 That prospective randomized trial included patients with GBCs and bile duct cancers (most of which were EHCs). Although those authors identified a survival benefit at 5 years for patients who had GBC treated with AC (26% vs 14.4%; P 5 .037), this benefit did not hold up in an intent-to-treat analysis, and the impact of adjuvant therapy on OS was not statistically significant on multivariable analysis. Conversely, our current study did not identify a survival advantage associated with the receipt of AC for the patients who had GBC. There are several potential reasons for this finding: First, in the Japanese trial, most patients in both the control (53%) and treatment (55%) arms underwent a margin-positive resection, calling into question whether the study truly addressed the role of "adjuvant" therapy. Next, the systemic therapy regimen used in the trial (mitomycin C and 5-fluorouracil administered on the day of surgery and starting on postoperative week 1, respectively), is not a commonly used approach in the United States. Finally, our findings are consistent with those from previous studies of AC for GBC in Western populations, in which no survival benefit has been consistently observed using this approach. 13, 19 Instead, our results corroborate earlier data supporting the use of AR for GBC. Separate analyses of Surveillance, Epidemiology, and End Results (SEER) and SEERMedicare data each reported a survival benefit from AR 20 and ACR, 21 especially among patients with lymph nodepositive GBC. Similarly, in an analysis of patients with stage I through III GBC from the NCDB (1998-2006), Hoehn et al reported improved survival with ACR but not with AC. 3 Our current work confirms and expands on these findings in a more contemporary patient cohort, going beyond the existing literature in demonstrating that resection is associated with a survival benefit in lymph node-positive GBC (and IHC) and that ACR confers a survival benefit even after margin-negative resection for these patients. The former is an especially important point that has not been widely reported, possibly leading to a nihilistic approach by clinicians who are managing patients who have lymph node-positive BTC. [5] [6] [7] There are even fewer quality studies regarding the role of adjuvant therapy for IHC. In a study of patients with IHC in the SEER database, AR was associated with a survival benefit over surgery alone. 16 An important shortcoming of any analysis using SEER data, however, is the lack of information on margin status. Given the infiltrative nature of IHC, accounting for the quality of surgical resection is critical in understanding the potential value of adjuvant therapy. In a recent review of patients who underwent surgical resection for IHC in the NCDB, AC was identified as beneficial for patients who had high-risk features, including positive-margin resection and lymph node involvement. 22 However, the authors did not separate out radiation therapy, which was received by 49.3% of patients who received AC and by only 4.4% of those who underwent surgery alone. Therefore, it was unclear whether the survival benefit described was associated with AC or, instead, was attributable to the addition of radiation. By accounting for this important distinction, we observed that, in fact, AC does not appear to be a beneficial adjuvant strategy for IHC. ACR likewise was not statistically associated with a survival advantage over surgery alone. It is noteworthy that our study was limited by a small sample size of patients with surgically resected, lymph node-positive IHC who received adjuvant therapy. Therefore, it may have been underpowered to detect a statistically significant benefit with adjuvant therapy. Still, our data support current national guidelines arguing for consideration of surgical resection in the setting of lymph node-positive disease, which should not be viewed as a contraindication to surgery.
Emerging data from several prospective trials are beginning to shed some light on this important topic. The BILCAP study randomized 447 patients with cholangiocarcinoma and GBC, 46% of whom were lymph node-negative, to receive either capecitabine or observation after undergoing complete resection. OS, which was the primary endpoint, was significantly better in the capecitabine group (51 vs 36 months), establishing capecitabine as a possible new standard of care. 8 We suspect that the difference between our results and those from the BILCAP trial with regard to the value of AC likely stems from the chemotherapy regimen used. Unlike BILCAP, which was conducted in the United Kingdom, systemic therapy for BTC in the United States can be variable and is often based on gemcitabine. In addition, our results suggest that radiotherapy may represent an important component of adjuvant therapy, at least in patients with GBC, and future trials comparing capecitabine versus capecitabine combined with radiation may be warranted. In this regard, Southwest Oncology Group Trial SWOG S0809, a phase 2, single-arm trial studying adjuvant combination gemcitabine-capecitabine followed by concurrent capecitabine-radiotherapy in 79 patients with GBC and EHC, demonstrated good tolerance of this regimen with favorable survival outcomes (2-year OS, 65%; median survival, 35 months) and forms the basis for possible future phase 3 trials. 23 The French phase 3 PRODIGE 12 trial, conversely, compared adjuvant combination gemcitabine-oxaliplatin versus surveillance after marginnegative or R1 resection of BTCs. 10 That study's primary endpoints were recurrence-free survival and health-related quality of life. The results were recently presented at a national meeting and demonstrated that this adjuvant treatment was feasible and did not negatively impact quality of life, although recurrence-free survival did not differ between the 2 arms (log-rank P 5 .31). Perhaps the most eagerly anticipated results are those from the currently accruing ACTICCA-1 randomized, multinational, multidisciplinary phase 3 trial, which compares adjuvant gemcitabine-cisplatin versus observation after curative intent resection for cholangiocarcinoma and GBC. 11 That trial is important for 2 main reasons: first, it uses a chemotherapy regimen that has been demonstrated to improve survival for unresectable and metastatic BCT over gemcitabine alone, based on the ABC-02 trial 24 ; and, second, it makes a point to separate trial enrollees into 2 separate disease sites, an important consideration given the disparate nature of the 2 disease processes.
The results presented in our work should be interpreted in light of some notable limitations. First, different types of selection bias could have influenced our findings. Given the observational nature of NCDB data and the lack of information on the severity of underlying liver disease (eg, the degree of cirrhosis) as well as other clinical factors that could have impacted clinical decision making, we used a landmark approach in our survival analyses to address the issues of survivor-treatment bias and confounding by indication. 12 Although this approach is frequently used in analyses of NCDB data to address these sources of bias to the extent possible, we acknowledge that residual bias remains a possibility. The NCDB does not provide information on the specific type of chemotherapy regimen received or the amount of chemotherapy administered. Also, with regard to nonoperative therapy, NCDB does not provide information about whether radiation was received concurrently with chemotherapy. In addition, information regarding tumor recurrence and disease-free survival is not available. Finally, it should be noted that the final sample sizes for patients with IHC who underwent surgery and received AC and ACR were both limited to <80 patients, such that meaningful conclusions regarding the value of adjuvant therapy for patients with resected IHC could not be drawn.
In conclusion, data are scarce with which to guide the clinical management of BTC, particularly when lymph node metastases are identified. Until the results from ongoing and completed prospective clinical trials become available, our study provides important data that can be used to direct the multimodal care of patients with lymph node-positive BTC. Specifically, surgical resection is associated with a survival benefit for patients who have lymph node-positive GBC and IHC. Although we recognize that there are unmeasured factors not captured in the NCDB likely contributing to the low resection rates for BTC (in particular for IHC), our results nonetheless suggest that positive lymph node status should not be considered a contraindication to resection in patients who are otherwise surgical candidates, and hopefully the findings provide important data supporting more aggressive surgical management of these aggressive tumors. [5] [6] [7] Furthermore, radiation should be considered in the management of all patients who have lymph node-positive GBC. The value of adjuvant therapy for lymph node-positive IHC beyond capecitabine remains unclear and warrants further investigation. These data can help to inform providers and patients when making clinical decisions about surgery and the use of adjuvant therapy at the point of care. 
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